Komori

Financial Results Briefing Materials for the Fiscal Year Ending September 2026

Results presentationFull year, FY ending Sep 2026Published 2026-11-16 16:00

In the fiscal year ending September 2026, revenue increased following the opening of new facilities, while EBITDA and profit declined due to higher personnel expenses and the impact of revisions to medical service fees. The company transferred 47 医心館 facilities in western Japan and will concentrate its management resources on the Tokyo metropolitan area and eastern Japan, as well as its comprehensive medical support and DX/AI businesses.

In short

  • Revenue increased 1.9% year on year to ¥50.1 billion, while EBITDA decreased 16.7% to ¥7.4 billion.
  • The company will transfer 47 医心館 facilities, primarily in western Japan, for ¥17.4 billion and expects a gain on sale of approximately ¥7.9 billion in the fiscal year ending September 2027.
  • For the fiscal year ending September 2027, revenue of ¥35.6 billion and operating profit of ¥1.1 billion are forecast, while net income is expected to reach ¥5.3 billion due to the gain on sale.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥50.1bn+1.9%vs a year earlier
FY FY25/9¥49.2bnFY FY26/9¥50.1bn
FY24/9FY25/9FY26/9 · this year1012¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+10%+5%+1%this yearvs same quarter last yearlast year
Sales by quarter
Period¥bn
FY24/9 Q19.5
FY24/9 Q210.1
FY24/9 Q311.1
FY24/9 Q411.8
FY25/9 Q111.8
FY25/9 Q212.0
FY25/9 Q312.5
FY25/9 Q412.8
FY26/9 Q112.9
FY26/9 Q212.7
FY26/9 Q312.7
last forecast 50.0
result 50.1
Full year: forecast against result, ¥bn+0.2% vs the last forecast
Next year's forecast: ¥35.6bn
Old and new forecast from the company's results releases
Why

Revenue increased due to the opening and ramp-up of facilities.

施設稼働率が低下しているものの、施設の開設と立ち上がりにより増収
Revenue increased due to the opening and ramp-up of facilities, despite lower facility utilization.
Forecast

Revenue is expected to decline in the fiscal year ending September 2027 due to the transfer of the 医心館 business and other factors.

医心館事業が減収減益となるため売上と営業利益は前年比で減少
Revenue and operating profit are expected to decline year on year because the 医心館 business will post lower revenue and profit.

Operating profit

¥4.0bn−34.5%vs a year earlier
FY FY25/9¥6.2bnFY FY26/9¥4.0bn
FY24/9FY25/9FY26/9 · this year0123¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4−21%−30%−14%this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥bn
FY24/9 Q12.6
FY24/9 Q22.7
FY24/9 Q32.8
FY24/9 Q42.5
FY25/9 Q12.0
FY25/9 Q21.7
FY25/9 Q31.0
FY25/9 Q41.5
FY26/9 Q11.6
FY26/9 Q21.2
FY26/9 Q30.8
last forecast 4.0
result 4.0
Full year: forecast against result, ¥bn+0.9% vs the last forecast
Next year's forecast: ¥1.1bn
Old and new forecast from the company's results releases
Why

Profit declined due to higher personnel expenses and the impact of revisions to medical service fees.

シフトチェンジによる人件費上昇と診療報酬改定による影響で、EBITDAは減少
EBITDA declined due to higher personnel expenses resulting from shift changes and the impact of revisions to medical service fees.
Forecast

Operating profit of ¥1.1 billion is forecast for the fiscal year ending September 2027.

Net profit

¥1.3bn−65.1%vs a year earlier
FY FY25/9¥3.7bnFY FY26/9¥1.3bn
FY24/9FY25/9FY26/9 · this year012¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4−20%−39%+90%this yearvs same quarter last yearlast year
Net profit by quarter
Period¥bn
FY24/9 Q11.8
FY24/9 Q22.0
FY24/9 Q31.9
FY24/9 Q41.7
FY25/9 Q11.3
FY25/9 Q21.3
FY25/9 Q30.3
FY25/9 Q40.7
FY26/9 Q11.1
FY26/9 Q20.8
FY26/9 Q30.6
last forecast 1.3
result 1.3
Full year: forecast against result, ¥bn+2.2% vs the last forecast
Next year's forecast: ¥5.3bn
Old and new forecast from the company's results releases
Forecast

A substantial increase in profit is expected due to the gain on the sale of the western Japan area.

医心館西日本エリアの譲渡益の計上により当期純利益は大幅増益
Net income is expected to increase substantially due to recognition of the gain on the sale of 医心館 facilities in western Japan.

Dividend

cash paid per share for the year, and how much of profit that is
¥4unchangedper share
last year¥4FY27/9 plan¥4

Shareholder dividends: The basic policy is to maintain stable shareholder dividends, taking comprehensive account of market conditions, regulatory trends and financial soundness, and to pay an annual year-end dividend.

Their own numbers

figures this company chose to report, a year ago against now
Utilization at existing facilities
73.8 %

Utilization of existing facilities was 73.8%.

Utilization at new facilities
41 %

Utilization of new facilities opened in the fiscal year ended September 2026 was 41.0%.

Number of Ishinkan facilities
138 facilities · a year ago 130 facilities

The number of facilities at the end of the period increased from 130 in the previous year to 138.

Number of 医心館 beds
7,178 people · a year ago 6,706 people

The number of beds at the end of the period increased from 6,706 in the previous year to 7,178.

Percentage of end-of-life care provided in facilities
98.9 %

The in-facility end-of-life care rate was 98.9%.

Customer Satisfaction
8.8 out of 10stated

Average customer satisfaction was 8.80 points.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

By business

bar = share of sales · rows = operating profit and change vs a year earlier
Ishinkan (medical care housing) business 98%
sales ¥48.9bn +0.6%
profit ¥3.3bn −44.9%
Comprehensive Medical Support Business 2%
sales ¥1.2bn +220.0%
profit ¥0.8bn +230.0%

What moved

change vs a year earlier, by the company's own breakdown
EBITDA
Change in revenue from existing facilities−¥0.9bn
Increase in personnel expenses at existing facilities (cost of sales)−¥1.0bn
Revenue increase from new facilities+¥1.1bn
Increase in personnel expenses at new facilities (cost of sales)−¥0.8bn
Increase in land rents and rent expenses (cost of sales)−¥0.2bn
Increase in personnel expenses (SG&A)−¥0.6bn
Other+¥0.9bn
Bar colour is the direction of the amount (red = up, teal = down).

New initiatives

what they said they're starting
  • The company will transfer 47 医心館 facilities, primarily in western Japan, to NSSK and concentrate its management resources on the Tokyo metropolitan area and eastern Japan.
  • The comprehensive medical support business offers 3 services: management consulting, financial support and trading company functions.
  • The Company will establish AIZIA, a subsidiary responsible for developing and selling DX/AI systems, among other activities, and expand into the healthcare, nursing care and welfare sectors.
  • The Ishinkan medical care facility business will be entrusted to the next generation, while senior management focuses on company-wide strategy and expanding growth areas.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago12.5%now8.1%

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity10.6%
profit earned on shareholders' money
−14.3 pts on last year
9%19%29%FY21/9FY22/9FY23/9FY24/9FY25/9FY21/9: 24.4%FY22/9: 23.3%FY23/9: 26.9%FY24/9: 24.9%FY25/9: 10.6%10.6%
Return on equity
Period%
FY21/924.4
FY22/923.3
FY23/926.9
FY24/924.9
FY25/910.6
Equity ratio43.0%
how much of the balance sheet is owned outright
−3.3 pts on last year
41%47%53%FY21/9FY22/9FY23/9FY24/9FY25/9FY21/9: 51.2%FY22/9: 49.0%FY23/9: 47.7%FY24/9: 46.3%FY25/9: 43.0%43.0%
Equity ratio
Period%
FY21/951.2
FY22/949.0
FY23/947.7
FY24/946.3
FY25/943.0
Payout ratio10.7%
share of profit paid as dividends
+5.4 pts on last year
3%8%13%FY21/9FY22/9FY23/9FY24/9FY25/9FY21/9: 8.0%FY22/9: 6.8%FY23/9: 4.7%FY24/9: 5.3%FY25/9: 10.7%10.7%
Payout ratio
Period%
FY21/98.0
FY22/96.8
FY23/94.7
FY24/95.3
FY25/910.7

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

How they rate themselves against plan

the company's own grade for the period, next to the numbers
What they said
Mixed against plan

On a consolidated basis, revenue and net income fell below the initial forecasts, while EBITDA and operating profit met them, and the comprehensive medical support business significantly exceeded its initial forecast.

営業利益、経常利益で期初予想を達成
The initial forecasts for operating profit and ordinary profit were achieved.
What the numbers say
−39%Net income vs plan
Revenue
plan ¥51.7bn · got ¥50.1bn
−3%
EBITDA
plan ¥7.1bn · got ¥7.5bn
+5%
Operating income
plan ¥3.8bn · got ¥4.0bn
+6%
Net income
plan ¥2.1bn · got ¥1.3bn
−39%

The line is the plan; a bar grows right by how far the result beat it and left by how far it missed, as a share of the plan.

Assumptions behind the forecast

what they expect for the rest of the year, against what's happened so far
医心館 opening plan
assumed 5 facilities · so far 9 facilities
so far
assumed

Store or site count

Number of Ishinkan facilities
130→138+8
9 new
there a year agonew this yearlost

Market size and share

square area = market size · a year ago outlined, now filled
Number of cancer deaths in Japan
Presented as the target market for the 医心館 business.
market
4010,000 people
Number of hospital beds in Japan
Presented as the target market for the comprehensive medical support business.
market
15010,000 beds

The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.

Not mentioned in this deck

9
Capital spendingShare buybackRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeHeadcountInvestor Q&A
Financial Results Briefing Materials for the Fiscal Year Ending September 2026 | Amvis Holdings,Inc. (7071) timely disclosure | Komori